Skip to main content
Top

Open Access 09-04-2024 | Vaccination | Current Opinion

Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination

Authors: María Gordillo-Marañón, Gianmario Candore, Karin Hedenmalm, Kate Browne, Robert Flynn, Loris Piccolo, Aniello Santoro, Cosimo Zaccaria, Xavier Kurz

Published in: Drug Safety

Login to get access

Abstract

During the COVID-19 vaccination campaign, observed-to-expected analysis was used by the European Medicines Agency to contextualise data from spontaneous reports to generate real-time evidence on emerging safety concerns that may impact the benefit-risk profile of COVID-19 vaccines. Observed-to-expected analysis compares the number of cases spontaneously reported for an event of interest after vaccination (‘observed’) to the ‘expected’ number of cases anticipated to occur in the same number of individuals had they not been vaccinated. Observed-to-expected analysis is a robust methodology that relies on several assumptions that have been described in regulatory guidelines and scientific literature. The use of observed-to-expected analysis to support the safety monitoring of COVID-19 vaccines has provided valuable insights and lessons on its design and interpretability, which could prove to be beneficial in future analyses. When undertaking an observed-to-expected analysis within the context of safety monitoring, several aspects need attention. In particular, we emphasise the importance of stratified and harmonised data collection both for vaccine exposure and spontaneous reporting data, the need for alignment between coding dictionaries and the crucial role of accurate background incidence rates for adverse events of special interest. While these considerations and recommendations were determined in the context of the COVID-19 mass vaccination setting, they are generalisable in principle.
Literature
2.
go back to reference Durand J, Dogné J-M, Cohet C, Browne K, Gordillo-Marañón M, Piccolo L, et al. Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency. Clin Pharmacol Ther. 2023;113:1223–34.CrossRefPubMed Durand J, Dogné J-M, Cohet C, Browne K, Gordillo-Marañón M, Piccolo L, et al. Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency. Clin Pharmacol Ther. 2023;113:1223–34.CrossRefPubMed
5.
go back to reference Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25:215–22.CrossRefPubMed Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25:215–22.CrossRefPubMed
14.
15.
go back to reference Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373: n1435.CrossRefPubMed Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373: n1435.CrossRefPubMed
16.
go back to reference Burn E, Li X, Kostka K, Morgan Stewart H, Reich C, Seager S, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 25.4 million people in six European countries. Hematology. 2022;31(5):495–510. Burn E, Li X, Kostka K, Morgan Stewart H, Reich C, Seager S, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 25.4 million people in six European countries. Hematology. 2022;31(5):495–510.
18.
19.
go back to reference Marques J, Ribeiro-Vaz I, Pereira AC, Polónia J. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal. Int J Pharm Pract. 2014;22:275–82.CrossRefPubMed Marques J, Ribeiro-Vaz I, Pereira AC, Polónia J. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal. Int J Pharm Pract. 2014;22:275–82.CrossRefPubMed
20.
go back to reference Sandberg A, Salminen V, Heinonen S, Sivén M. Under-reporting of adverse drug reactions in Finland and healthcare professionals’ perspectives on how to improve reporting. Healthcare (Basel). 2022;10:1015.CrossRefPubMedPubMedCentral Sandberg A, Salminen V, Heinonen S, Sivén M. Under-reporting of adverse drug reactions in Finland and healthcare professionals’ perspectives on how to improve reporting. Healthcare (Basel). 2022;10:1015.CrossRefPubMedPubMedCentral
23.
go back to reference Maignen F, Hauben M, Tsintis P. Modelling the time to onset of adverse reactions with parametric survival distributions. Drug Saf. 2010;33:417–34.CrossRefPubMed Maignen F, Hauben M, Tsintis P. Modelling the time to onset of adverse reactions with parametric survival distributions. Drug Saf. 2010;33:417–34.CrossRefPubMed
24.
go back to reference Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, et al. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nat Commun. 2022;13:25.CrossRefPubMedPubMedCentral Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, et al. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nat Commun. 2022;13:25.CrossRefPubMedPubMedCentral
25.
go back to reference Mozzicato P. Standardised MedDRA queries: their role in signal detection. Drug Saf. 2007;30:617–9.CrossRefPubMed Mozzicato P. Standardised MedDRA queries: their role in signal detection. Drug Saf. 2007;30:617–9.CrossRefPubMed
33.
go back to reference Priyadarshni S, Westra J, Kuo Y-F, Baillargeon JG, Khalife W, Raji M. COVID-19 infection and incidence of myocarditis: a multi-site population-based propensity score-matched analysis. Cureus. 2022;14: e21879.PubMedPubMedCentral Priyadarshni S, Westra J, Kuo Y-F, Baillargeon JG, Khalife W, Raji M. COVID-19 infection and incidence of myocarditis: a multi-site population-based propensity score-matched analysis. Cureus. 2022;14: e21879.PubMedPubMedCentral
34.
go back to reference Keller K, Sagoschen I, Konstantinides S, Gori T, Münzel T, Hobohm L. Incidence and risk factors of myocarditis in hospitalized patients with COVID-19. J Med Virol. 2023;95: e28646.CrossRefPubMed Keller K, Sagoschen I, Konstantinides S, Gori T, Münzel T, Hobohm L. Incidence and risk factors of myocarditis in hospitalized patients with COVID-19. J Med Virol. 2023;95: e28646.CrossRefPubMed
35.
go back to reference Ostropolets A, Li X, Makadia R, Rao G, Rijnbeek PR, Duarte-Salles T, et al. Factors influencing background incidence rate calculation: systematic empirical evaluation across an international network of observational databases. Front Pharmacol. 2022;13: 814198.CrossRefPubMedPubMedCentral Ostropolets A, Li X, Makadia R, Rao G, Rijnbeek PR, Duarte-Salles T, et al. Factors influencing background incidence rate calculation: systematic empirical evaluation across an international network of observational databases. Front Pharmacol. 2022;13: 814198.CrossRefPubMedPubMedCentral
36.
go back to reference Russek M, Quinten C, de Jong VMT, Cohet C, Kurz X. Assessing heterogeneity of electronic health-care databases: a case study of background incidence rates of venous thromboembolism. Pharmacoepidemiol Drug Saf. 2023;32:1032–48.CrossRefPubMed Russek M, Quinten C, de Jong VMT, Cohet C, Kurz X. Assessing heterogeneity of electronic health-care databases: a case study of background incidence rates of venous thromboembolism. Pharmacoepidemiol Drug Saf. 2023;32:1032–48.CrossRefPubMed
Metadata
Title
Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination
Authors
María Gordillo-Marañón
Gianmario Candore
Karin Hedenmalm
Kate Browne
Robert Flynn
Loris Piccolo
Aniello Santoro
Cosimo Zaccaria
Xavier Kurz
Publication date
09-04-2024
Publisher
Springer International Publishing
Published in
Drug Safety
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-024-01422-8